Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
$9.84
-$0.35(-4.35%)
At close: 4:00 PM EST
$9.84
-$0.35(-4.35%)
Day’s Range― - ―
52-Week Range$5.41 - $19.73
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.76M
Market Cap
$879.26M
Enterprise Value-$105.88M
Total Cash (Recent Filing)$630.73M
Total Debt (Recent Filing)$12.96M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Oct 30, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding86,797,190
10 Day Avg. Volume1,794,955
30 Day Avg. Volume1,756,343
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-1.27
Enterprise Value/Gross Profit-1.28
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$26.00Price Target Upside164.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe launch of the FLT3/NPM1 co-mutation arm in the KOMET-007 trial represents a significant advancement in treating AML patients with poor prognosis.
Drug ApprovalUpcoming potential approval and ongoing studies establish a strong foundation for ziftomenib's ability to target multiple AML settings and mutations.
Therapeutic PotentialZifto’s therapeutic profile is primarily characterized by strong efficacy signal, simplicity, compatibility, and favorable safety.
Bears Say
Drug ResistanceDespite important clinical progress with small-molecule targeted therapies, resistance limits the potential of these drugs, and their efficacy as monotherapy may be restricted.
Market SentimentYesterday’s presentation is unlikely to shift sentiment much, with the checkered history of the class and its early stage likely keeping this a 'show-me' story for most.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.41 and its highest was $19.73 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $879.26M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 30, 2025 which is in 12 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Aug 07, 2025. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.366 by -$0.384.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.73.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 86,797,190 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.366. Following the earnings report the stock price went down -7.047%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
Kura Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (164.23% Upside)
$26.00 (164.23% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $198.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.55%
12-Months-Change
Fundamentals
Return on Equity
-51.11%
Trailing 12-Months
Asset Growth
32.48%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KURA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results, regulatory progress, and financial stability, indicating positive momentum for Kura Oncology's lead program, ziftomenib, and its pipeline. However, increased expenses and net loss present financial challenges. The sentiment is positive overall due to significant advancements and strong financial positioning.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$26.00
▲(164.23% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Ownership Overview
1.83% Insiders
10.82% Mutual Funds
1.64% Other Institutional Investors
72.06% Public Companies and
Individual Investors